Therapeutic efficacy of nanoparticles and routes of administration

Abstract

In modern-day medicine, nanotechnology and nanoparticles are some of the indispensable tools in disease monitoring and therapy. The term “nanomaterials” describes materials with nanoscale dimensions (< 100 nm) and are broadly classified into natural and synthetic nanomaterials. However, “engineered” nanomaterials have received significant attention due to their versatility. Although enormous strides have been made in research and development in the field of nanotechnology, it is often confusing for beginners to make an informed choice regarding the nanocarrier system and its potential applications. Hence, in this review, we have endeavored to briefly explain the most commonly used nanomaterials, their core properties and how surface functionalization would facilitate competent delivery of drugs or therapeutic molecules. Similarly, the suitability of carbon-based nanomaterials like CNT and QD has been discussed for targeted drug delivery and siRNA therapy. One of the biggest challenges in the formulation of drug delivery systems is fulfilling targeted/specific drug delivery, controlling drug release and preventing opsonization. Thus, a different mechanism of drug targeting, the role of suitable drug-laden nanocarrier fabrication and methods to augment drug solubility and bioavailability are discussed. Additionally, different routes of nanocarrier administration are discussed to provide greater understanding of the biological and other barriers and their impact on drug transport. The overall aim of this article is to facilitate straightforward perception of nanocarrier design, routes of various nanoparticle administration and the challenges associated with each drug delivery method.

References 257

1. 1.

   Tarafdar JC, Sharma S, Raliya R. Nanotechnology: Interdisciplinary science of applications. Afr J Biotechnol. 2013;12(3):219-226.

   Not in our library10.5897/ajb12.2481

2. 2.

   Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs–a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol. 2004;113(1):151-170.

   Not in our library10.1016/j.jbiotec.2004.06.007

3. 3.

   Yhee JY, Son S, Kim N, Choi K, Kwon IC. Theranostic applications of organic nanoparticles for cancer treatment. MRS Bull. 2014;39(3):239-249.

   Not in our library10.1557/mrs.2014.30

4. 4.

   Kim T, Hyeon T. Applications of inorganic nanoparticles as therapeutic agents. Nanotechnology. 2013;25(1):012001.

   Not in our library10.1088/0957-4484/25/1/012001

5. 5.

   Kumar S, Dilbaghi N, Saharan R, Bhanjana G. Nanotechnology as emerging tool for enhancing solubility of poorly water-soluble drugs. Bionanoscience. 2012;2(4):227-250.

   Not in our library10.1007/s12668-012-0060-7

6. 6.

   Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63(3):131-135.

   Not in our library10.1016/j.addr.2010.03.011

7. 7.

   Bamrungsap S, Zhao Z, Chen T, Wang L, Li C, Fu T, Tan W, et al. Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system. Nanomedicine. 2012;7(8):1253-1271.

   Not in our library10.2217/nnm.12.87

8. 8.

   Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70(1–2):1-20.

   Not in our library10.1016/s0168-3659(00)00339-4

9. 9.

   Liu Z, Jiao Y, Wang Y, Zhou C, Zhang Z. Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliv Rev. 2008;60(15):1650-1662.

   Not in our library10.1016/j.addr.2008.09.001

10. 10.

    Lü JM, Wang X, Marin-Muller C, Wang H, Lin PH, Yao Q, Chen C, et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn. 2009;9(4):325-341.

    Not in our library10.1586/erm.09.15

11. 11.

    Andonova V, Boreddy SR. Synthetic Polymer-Based Nanoparticles: Intelligent Drug Delivery Systems. Acrylic Polymers in Healthcare. 2017;101-125.

    Not in our library

12. 12.
    Chitosan and Its Derivatives for Application in Mucoadhesive Drug Delivery Systems · 2018

    No notice
13. 13.

    Sajomsang W, Ruktanonchai UR, Gonil P, Nuchuchua O. Mucoadhesive property and biocompatibility of methylated N-aryl chitosan derivatives. Carbohydr Polym. 2009;78(4):945-952.

    Not in our library10.1016/j.carbpol.2009.07.020

14. 14.

    Thanou M, Florea BI, Langemeyer MW, Verhoef JC, Junginger HE. N-trimethylated chitosan chloride (TMC) improves the intestinal permeation of the peptide drug buserelin in vitro (Caco-2 cells) and in vivo (rats). Pharm Res. 2000;17(1):27-31.

    Not in our library10.1023/a:1007558206506

15. 15.

    Gatti TH, Eloy JO, Ferreira LM, Silva IC, Pavan FR, Gremião MP, Chorilli M. Insulin-loaded polymeric mucoadhesive nanoparticles: development, characterization and cytotoxicity evaluation. Braz J Pharm Sci. 2018;54:1-10.

    Not in our library10.1590/s2175-97902018000117314

16. 16.

    Calvo P, Gouritin B, Villarroya H, Eclancher F, Giannavola C, Klein C, Andreux JP, Couvreur P, et al. Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. EJN. 2002;15(8):1317-1326.

    Not in our library10.1046/j.1460-9568.2002.01967.x

17. 17.

    Faraji AH, Wipf P. Nanoparticles in cellular drug delivery. Bioorg Med Chem. 2009;17(8):2950-2962.

    Not in our library10.1016/j.bmc.2009.02.043

18. 18.

    Athanasiou KA, Niederauer GG, Agrawal CM. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials. 1996;17(2):93-102.

    Not in our library10.1016/0142-9612(96)85754-1

19. 19.

    Tosi G, Bortot B, Ruozi B, Dolcetta D, Vandelli MA, Forni F, Severini GM, et al. Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier. Curr Med Chem. 2013;20(17):2212-2225.

    Not in our library10.2174/0929867311320170006

20. 20.

    Badri W, Eddabra R, Fessi H, Elaissari A. Biodegradable polymer based nanoparticles: dermal and transdermal drug delivery. J Colloid Sci. 2014;3(2):141-149.

    Not in our library

21. 21.

    Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1-8.

    Not in our library10.1016/j.colsurfb.2009.09.001

22. 22.

    Hedley ML, Curley J, Urban R. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat Med. 1998;4(3):365-368.

    Not in our library10.1038/nm0398-365

23. 23.

    Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003;55(3):329-347.

    Not in our library10.1016/s0169-409x(02)00228-4

24. 24.

    Fadel M, Kassab K, Fadeel DA. Zinc phthalocyanine-loaded PLGA biodegradable nanoparticles for photodynamic therapy in tumor-bearing mice. Lasers Med Sci. 2010;25(2):283-292.

    Not in our library10.1007/s10103-009-0740-x

25. 25.
    An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery · 2017

    No notice
26. 26.

    Raftery R, O'Brien F, Cryan SA. Chitosan for gene delivery and orthopedic tissue engineering applications. Molecules. 2013;18(5):5611-5647.

    Not in our library10.3390/molecules18055611

27. 27.

    Janes KA, Calvo P, Alonso MJ. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliv Rev. 2001;47(1):83-97.

    Not in our library10.1016/s0169-409x(00)00123-x

28. 28.

    Patel MP, Patel RR, Patel JK. Chitosan mediated targeted drug delivery system: a review. J Pharm Pharm Sci. 2010;13(4):536-557.

    Not in our library10.18433/j3jc7c

29. 29.

    Tozaki H, Odoriba T, Okada N, Fujita T, Terabe A, Suzuki T, Okabe S, Muranishi S, Yamamoto A, et al. Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. J Control Release. 2002;82(1):51-61.

    Not in our library10.1016/s0168-3659(02)00084-6

30. 30.

    Rodrigues LB, Leite HF, Yoshida MI, Saliba JB, Junior AS, Faraco AA, et al. In vitro release and characterization of chitosan films as dexamethasone carrier. Int J Pharm. 2009;368(1–2):1-6.

    Not in our library10.1016/j.ijpharm.2008.09.047

31. 31.

    Yuan ZX, Sun X, Gong T, Ding H, Fu Y, Zhang ZR, et al. Randomly 50% N-acetylated low molecular weight chitosan as a novel renal targeting carrier. J Drug Target. 2007;15(4):269-278.

    Not in our library10.1080/10611860701289875

32. 32.

    Pandey H, Rani R, Agarwal V. Liposome and their applications in cancer therapy. Braz Arch Biol Technol. 2016;59:e16150477.

    Not in our library10.1590/1678-4324-2016150477

33. 33.
    Solid Lipid Nanoparticles: Emerging Colloidal Nano Drug Delivery Systems · 2018

    No notice
34. 34.

    Uchechi O, Ogbonna JD, Attama AA. Nanoparticles for dermal and transdermal drug delivery. Application of Nanotechnology in Drug Delivery. 2014;193-235.

    Not in our library

35. 35.

    Xue M, Yang MX, Zhang W, Li XM, Gao DH, Ou ZM, Li ZP, Liu SH, Li XJ, Yang SY, et al. Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles. Int J Nanomedicine. 2013;8:4677.

    Not in our library10.2147/ijn.s51262

36. 36.

    Chen R, Wang S, Zhang J, Chen M, Wang Y. Aloe-emodin loaded solid lipid nanoparticles: formulation design and in vitro anti-cancer study. Drug deliv. 2015;22(5):666-674.

    Not in our library10.3109/10717544.2014.882446

37. 37.

    Baek JS, Cho CW. Surface modification of solid lipid nanoparticles for oral delivery of curcumin: Improvement of bioavailability through enhanced cellular uptake, and lymphatic uptake. Eur J Pharm Biopharm. 2017;117:132-140.

    Not in our library10.1016/j.ejpb.2017.04.013

38. 38.

    Svenson S. The dendrimer paradox–high medical expectations but poor clinical translation. Chem Soc Rev. 2015;44(12):4131-4144.

    Not in our library10.1039/c5cs00288e

39. 39.

    Labieniec-Watala M, Watala C. PAMAM dendrimers: destined for success or doomed to fail? Plain and modified PAMAM dendrimers in the context of biomedical applications. J Pharm Sci. 2015;104(1):2-14.

    Not in our library10.1002/jps.24222

40. 40.

    Jain Keerti, Kesharwani Prashant, Gupta Umesh, Jain N.K. Dendrimer toxicity: Let's meet the challenge. International Journal of Pharmaceutics. 2010;394(1-2):122-142.

    Not in our library10.1016/j.ijpharm.2010.04.027

Cited by papers we hold 3

• A Review on Polymer and Lipid-Based Nanocarriers and Its Application to Nano-Pharmaceutical and Food-Based Systems · 2021
  No notice
• Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems · 2020
  No notice
• Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.